Head Of Australia's Sigma Resigns In Face of Large Losses
This article was originally published in PharmAsia News
Sigma Pharmaceuticals Managing Director Elmo de Alwis resigned his post in the wake of large losses recorded by the Australian drug maker. The director has held the post since Sigma went public in 2002, and led the firm into its acquisition of Arrow Pharmaceuticals in 2005. Company earnings have been on the decline for the past three years, leading to assertions the firm failed to disclose information key to potential investors. (Click here for more
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.